1VanDerHeijde DM. Joint erosions and the patient with early rheumatoid arthritis. BrJ Rheumatol, 1995, 34 (Snppl 2) :74 - 78.
2Wolfe F, Hawley DJ, Cathey MA. Termination of alow acting antirheumatic therapy in rheumatoid arthri is:l 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol, 1990, 17:994 -1002.
3Klinkhoff A. Biological agents for rheumatoid arthritis:targeting both physical function and structural danmge. Drugs, 2004, 64:1267 -1283.
4Moreland LW, Baumgartner SW, Schiff Mtt, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor-Fc fusion protein. N Engl Med, 1997, 337:141 - 147.
5Mohler KM, Torrance DS, mith CA, et al. Soluble tumor necrosis factor(TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol, 1993, 151:1548- 1561.
6Feldmann M, Elliott M J, Woody N J, et al. Anti-tumor necrosis factora therapy of rheumatoid arthritis. Adv Immunol, 1997, 64:283 - 350.
7Elliott M J, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor-a. Arthritis Rheum, 1993, 36:1681 - 1690.
8St Clair EW, Wagner CL, Fasanmade AA, et al. The relationship between inflixinmb concentrations to clinical improvement in rheumatoid arthritis:results from ATI'RACT, a multi-center randomized,double-blind, placebo-controlled trial. Arthritis Rheum, 2002, 46:1451 - 1459.
9Den Broeder A, Van De Putte KBA. A single dose,placebo controlled study of the fully human anti-tumor necrosis factor-a antibody, Adalimumab, (D2E7) in patients with rheumatoid arthritis. J Rheumatol, 2002, 29:2288 - 2298.
10Weinblatt ME, Keystone EC, Furst DE. Adalimumab, a fully human anti-tumor necrosis factor-a monoclonal antibody for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate:the ARMADA trial. Arthritis Rheum,2003, 48:35 - 45.
